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Recent evidence shows divergence between the concentrations of extracellular 70 kDa heat shock protein [eHSP70] and its
intracellular concentrations [iHSP70] in people with type 2 diabetes (T2DM). A vital aspect regarding HSP70 physiology is its
versatility to induce antagonistic actions, depending on the location of the protein. For example, iHSP70 exerts a powerful anti-
inflammatory effect, while eHSP70 activates proinflammatory pathways. Increased eHSP70 is associated with inflammatory and
oxidative stress conditions, whereas decreased iHSP70 levels are related to insulin resistance in skeletal muscle. Serum eHSP70
concentrations are positively correlated with markers of inflammation, such as C-reactive protein, monocyte count, and TNF-𝛼,
while strategies to enhance iHSP70 (e.g., heat treatment, chemical HSP70 inducers or coinducers, and physical exercise) are capable
of reducing the inflammatory profile and the insulin resistance state. Here, we present recent findings suggesting that imbalances in
the HSP70 status, described by the [eHSP70]/[iHSP70] ratio, may be determinant to trigger a chronic proinflammatory state that
leads to insulin resistance and T2DM development. This led us to hypothesize that changes in this ratio value could be used as a
biomarker for the management of the inflammatory response in insulin resistance and diabetes.
1. Introduction
Heat shock proteins (HSPs) are considered part of a family of
proteins known as “stress proteins” since their expression is
induced by a wide range of stressors, such as oxidative stress
[1], thermal stress [2], ischemia [3], exercise [1], metabolic
stress [4], and many others. The 72 kDa member of the
70 kDa family of heat shock proteins, HSP70 (or HSPA,
encoded by theHSPA1A gene in humans), is inducible during
cell stress. It is the most abundant of all HSPs, accounting
for 1-2% of cellular protein [5], and is plentiful in skeletal
muscle [6]. Asmolecular chaperones, the intracellular HSP70
proteins (iHSP70) can interact with other proteins (unfolded,
in nonnative state and/or stress-denatured conformations)
to avoid inappropriate interactions, formation of protein
aggregates, and degradation of damaged proteins, as well as
helping the correct refolding of nascent proteins [6]. Other
functions include protein translocation [7], antiapoptosis
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[8], and anti-inflammatory responses [9, 10]. More recently,
the HSP roles have been expanded to include control of
cell signaling [11], modulation of immune response [12],
and modulation of chronic disease conditions [13] such as
diabetes, obesity, and insulin resistance [14, 15].
The heat shock response is regulated by a family of heat
shock transcription factors (HSFs) composed of four mem-
bers (HSF 1–4), which are maintained in an inactive mono-
meric form during nonstimulated conditions [16]. HSF-1 is
a primary regulator of heat shock response in mammalian
cells and a low concentration of it has been associated with
a number of human pathologies including T2DM [17] and
obesity-related fatty liver disease [18]. HSF-1 activation is
a multistep mechanism that involves its phosphorylation,
trimerization, nuclear translocation, and DNA binding to
heat shock elements (HSE) located at the promoter regions of
targeted heat shock genes [15]; nevertheless, HSF-1 activation
can be negatively regulated by posttranscriptional modifica-
tion, such as phosphorylation in specific serine residues and
phosphorylation-dependent sumoylation [19].
Heat shock proteins were long thought to be exclusive
cytoplasmic proteins with functions restricted to the intra-
cellular compartment. However, an increasing number of
observations have indicated that theymay be released into the
extracellular space (eHSP70) having a wide variety of effects
on other cells [20]. eHSP70 function is, in general, associated
with the activation of the immune system [21]. For example,
eHSP70 has been reported to stimulate neutrophil microbi-
cidal capacity [22] and chemotaxis [23] and recruitment of
natural killer (NK) cells [24] as well as cytokine production
by immune cells [12, 25]. In addition, eHSP70 was recently
hypothesized to be involved in the inducement of neural cell
protection under stress conditions [15].
An intriguing aspect of HSP70 physiology is its versatility
to induce antagonistic actions, depending on the location
of the protein [17]. For example, iHSP70 exerts a powerful
anti-inflammatory effect, while eHSP70 has the opposite
role, inducing the activation of several proinflammatory
pathways. In fact, chronic exposure to eHSP70 [26] induces
the activation of several proinflammatory pathways probably
via binding to membrane Toll-like receptors (see below)
although eHSP70-peptides have also been shown to act
as anti-inflammatory and immunosuppressive factors after
internalization and antigen processing (see Borges et al., 2012,
for review [27]).
iHSP70 exerts its anti-inflammatory effect through the
interaction with the nuclear factor 𝜅B (NF-𝜅B), blocking
its activation [28]. NF-𝜅B is a ubiquitous transcription fac-
tor originally discovered in B-lymphocytes that is essential
for arming inflammatory responses to a variety of signals,
immune function, endothelial cell activation, and the control
of cell growth [29]. iHSP70 hampers NF-𝜅B activation at
several levels, by impeding the phosphorylation of inhibitor
of 𝜅B (I𝜅Bs) [30], by directly binding to I𝜅B kinase gamma
(IKK𝛾) [31], which will result in continued binding (and
inactivation of NF-𝜅B) thus inhibiting downstream inflam-
matory signals. This is corroborated by the finding that
iHSP70 binds with liver NF-𝜅B/I𝜅B complex in the cytosol
thus hindering transcription of TNF𝛼 and inducible nitric
oxide synthase (NOS2) genes [31] which are activated via a
NF-𝜅B dependent mechanism. Stress-induced elevations in
iHSP70 inhibit c-Jun N-terminal kinase- (JNK-) dependent
signal transduction hence promoting cell survival [32].
iHSP70 affects apoptosis at various levels. It can inhibit
caspase activation by interfering with Apaf-1 and prevent the
recruitment of procaspase-9 to the apoptosome [33]. HSP70
also increases Bcl-2 expression and inhibits cytochrome C
release [34].Overexpression ofHSP70 in lymphoid tumor cell
lines inhibited apoptosis by attenuation of caspase activation
[35]. The antiapoptotic effects of HSP70 have been reported
for mouse brain tissue, where HSP70 overexpression resulted
in decreased infarct sizes, improved neurological deficits, and
fewer apoptotic cells (determined by reduced DNA ladder-
ing) after middle cerebral artery occlusion [36]. HSP70s have
also been shown to decrease oxidative stress so that they
are part of the intracellular antioxidant machinery, making
iHSP70 even more important for the inhibition of apoptosis
and inflammation [37]. Cyclopentenone prostaglandins (cp-
PGs), which under certain circumstances may induce HSP70
expression, are consequently powerful anti-inflammatory
autacoids [38–40].
The interplay between iHSP70 and proinflammatory
cytokines at gene regulatory level has also been reported.The
promoter region of TNF𝛼 gene contains an HSF1 binding
site that represses TNF𝛼 transcription, and thus loss of this
repressor results in sustained expression of TNF𝛼 [41]; thus
the HSF1 knockout is associated with a chronic elevation
of TNF𝛼 levels and increased susceptibility to endotoxin
challenge [42]. Regulation of such a network in the opposite
directions has also been demonstrated: TNF𝛼 may tran-
siently repress HSF1 activation [43]. Furthermore, JNK1 was
unequivocally demonstrated to phosphorylate HSF1 in its
regulatory domain causing suppression of HSF1 transcribing
activity [44] while HSP70 prevented Bax activation both by
inhibiting the JNK/Bim pathway and by interacting with Bax
in UV-induced apoptosis [45]. Altogether, the above findings
explain why the induction of HSP72 (HSPA1A) in vitro (by
heat shock or HSP72 transgene overexpression) reduces the
expression of inflammatory genes such as TNF𝛼, IL-1, IL-12,
IL-10, and IL-18 [46].
In contrast to the above findings, eHSP70 proinflam-
matory actions have been demonstrated to be mediated
by MyD88/IRAK/NF-𝜅B signal transduction pathway after
both Toll-like receptor 2 (TLR2) and TLR4 binding, in a
CD14-dependent manner [47, 48], thus promoting innate
immune activation [49]. Due to the antagonistic actions of
the heat shock proteins within the course of an inflam-
matory response, it is reasonable to hypothesize that the
balance between eHSP70 and iHSP70 might determine
the outcome—either the induction or the attenuation of
inflammation. Since low-grade inflammation is involved in
several chronic diseases [17], the management of HSP70
expression and its location can be crucial for the control of
inflammatory-related conditions, such as T2DM. We herein
suggest that the ratio of the extracellularmediumHSP70 con-
centration to intracellular HSP70 contents (eHSP70/iHSP70)
can determine the progress of insulin resistance and the
progression of T2DM.
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2. Obesity, Low-Grade Inflammation, and
Insulin Resistance
The incidence of T2DM has increased dramatically over the
last fifty years and this is clearly associated with growing
rates of obesity [50] and physical inactivity. Obesity is linked
to a chronic proinflammatory state, since adipose tissue
expansion and adipose associated immune cell activation
result in the release of several cytokines, such as TNF𝛼, which
leads to the activation of serine threonine kinases JNKs and
IKK [14]. It is known that both JNK and IKK phosphorylate
insulin receptor (IR) substrate-1 (IRS-1) on Ser-307, leading to
the inactivation of the insulin receptor downstream response
[14]. Also, chronic activation of IKK has been reported in
diabetic patients, while a reduction in IKK activity prevents
the development of insulin resistance in vitro and in vivo [51].
In addition, lipid oversupply and hyperglycemia can lead to
increased deposition of lipid species such as diacylglycerols
and ceramides, which can also activate JNK and IKK in
liver and/or skeletal muscle, leading to insulin resistance [52],
causing sustained hyperglycemia and hyperlipemia.
Hyperglycemia per se is also known to be involved in
inflammation and diabetes-associated vascular complica-
tions arising from reactive oxygen species generation and
action [53, 54]. Chronic hyperglycemia induces the pro-
duction of reactive oxygen species (ROS) [55], leading to
enhancement of protein oxidation, DNA oxidation, and lipid
peroxidation. The free radical gas nitric oxide (NO∙) also
plays a role in the insulin resistant state generated by pro-
inflammatory cytokines. NO∙ is synthesized at high rates by
the inducible form of nitric oxide synthase (iNOS, encoded
by the NOS-2 gene) which plays a significant role in cell
damage associated with obesity and T2DM. Interestingly, a
physiological concentration of this free radical is required
to stimulate necessary functions such as muscle GLUT4
expression/translocation [56] and insulin secretion by 𝛽-cells
[57]. However, at high concentrations, NO∙ compromises
insulin-stimulated glucose transport in skeletal muscle and
can also be toxic to 𝛽-cells inducing death. Accordingly, acute
treatment with NO∙ donors results in a reduction of insulin-
stimulated glucose uptake and glycogen synthesis in isolated
soleus muscle, inducing decreased IR𝛽 and IRS-1 activity.
In vivo, this treatment also promotes insulin resistance in
healthy animals by the reduction of IRS-1 levels. Obese
ob/ob mice or rats submitted to high fat diet (HFD) have
shown enhanced NOS-2 expression associated with insulin
receptor and Akt S-nitrosylation, which can be dismissed
by rosiglitazone treatment by virtue of its NOS-2 expression
inhibiting activity [58].
Expanded adipose tissue triggers the release of inter-
leukin-6 (IL-6) in obese subjects that is associated with
alterations in glucose uptake by the skeletal muscle [59].
Nevertheless, it is possible that there is a dual role of serum
IL-6 on glucosemetabolism, probably related to the exposure
time of and concentration of IL-6. Accordingly, acute IL-6
treatment may increase glucose uptake in C2C12 myotubes
by stimulating AMP-activated protein kinase (AMPK) in
a serine/threonine kinase 11- (LKB1-) dependent pathway,
which induces downstream AS160 activation [60], while
IL-6 may induce a modest increase in the glucose infusion
rate after 4 h of hyperinsulinemic-euglycemic clamp in mice
[61]. Moderate doses of IL-6 stimulate basal and insulin-
stimulated glucose uptake in L6 myotubes and 3T3 cells
line after 2 h [61]. In addition, physiological concentrations
of IL-6 were reported to stimulate insulin secretion by iso-
lated pancreatic islets and BRIN-BD11 clonal 𝛽-cells through
AMPK activation [62]. However, chronic treatment (24 h)
with this cytokine has been demonstrated to be able to cause
insulin resistance in C2C12 murine myotube cell line, due
to impairment of insulin signaling (IRS/AKT cascades) in a
JNK1/2-dependent manner [60].
Finally, obesity is often associated with a vicious cycle
in which adipose tissue expansion increases the levels of
free fatty acids (FFA) and proinflammatory cytokines in the
circulation, which together with hyperglycemia and altered
lipoprotein profiles increase the synthesis and accumulation
of intramyocellular triglycerides (IMCT) [63]. Sedentary
behavior and aging are conditions related to a decreased
mobilization of the IMCT resulting in an increased synthe-
sis of toxic fatty-acid-delivered metabolites (FADM). These
metabolites cause, in turn, an elevation in the production
of reactive oxygen and nitrogen species (ROS and RNS),
resulting in oxidative/nitrosative stress, mitochondrial dys-
function, and the activation of stress associated transcription
factors, such as NF-𝜅B, which is followed by increased
production and release of proinflammatory cytokines (e.g.,
TNF𝛼). TNF𝛼 is a major driver of insulin resistance in skele-
tal muscle and, in addition, it can also induce activation of
stress signals in pancreatic 𝛽-cells, leading to mitochondrial
dysfunction that culminates in cell failure and death [64].
3. Role of iHSP70 in Insulin Sensitivity
It has been reported that iHSP72 mRNA levels are decreased
in skeletal muscle of T2DM patients which is correlated
with the “status” of insulin resistance [65], whereas heat
shock-like therapies (i.e., whole body warming, transgenic
overexpression, or pharmacological mechanisms to elevate
HSPA1A protein expression) protect against high-fat-diet-
and obesity-induced hyperglycemia, hyperinsulinemia, glu-
cose intolerance, and insulin resistance [14, 65, 66]. Although
the underlying mechanism(s) culminating in lower iHSP70
expression in T2DM individuals are not fully understood, the
observed reductions are likely to be a result of the concerted
contribution of (i) reduction in the rate of HSP70 protein
synthesis due to attenuation of initiation and elongation
phases of translation, (ii) suppression of HSF-1 activation
and binding to HSE via an increase in glycogen synthase
kinase-3𝛽 activity (GSK-3𝛽) as previously suggested [67],
and (iii) decreased HSF1 expression. In this regard, it has
been recently proposed that long-term inflammatory stimuli
emanating from the adipose tissue of obese individuals could
repress HSF-1/iHSP70 axis because continuous activation
of inflammasome NLRP3 may lead to a state of cellular
senescence which abolishes the expression and activity of
HSF-1 [68]. In line with this is the observation that the
expression of both HSF-1 and iHSP70 in adipose tissue and
the liver of type III obese patients is dramatically reduced
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while the activation of JNKs is reciprocally enhanced in the
same tissues [18].
As discussed above, the anti-inflammatory effect of
iHSP70 is attributed mainly to its capacity of interaction with
NF-𝜅B. In fact, IKK-𝛽 and NF-𝜅B activity have been found to
be increased in different obese experimentalmodels. Chronic
activation of IKK has been reported in diabetic patients,
while a reduction in IKK activity prevents the development
of insulin resistance in vitro and in vivo [51]. High-fat,
high-carbohydrate intake may result in oxidative stress and
consequent NF-𝜅B activation in obese subjects [69]. On
the other hand, NF-𝜅B DNA binding is suppressed after
heat shock [70], and upregulation of HSPA1A can negatively
affect NF-𝜅B activity in skeletal muscle [71]. In addition,
overexpression of HSPA1A can restrict NO production and
release by transfected cells in amechanism dependent onNF-
𝜅B DNA binding and subsequent iNOS gene expression [70].
Heat treatment is capable of inducing HSPA1A expres-
sion in several tissues, preventing various obesity-elicited
metabolic effects at molecular level, leading to improvement
of glucose tolerance, insulin-stimulated glucose transport,
and insulin signaling accompanied by the reduction in JNK
and IKK𝛽 activities in skeletal muscle [72] and liver [14] of
HFD mice, which is almost completely abolished in trans-
genicHSPA1A+/+mice [14]. Furthermore, iHSP70 expression
has been shown to decrease JNK activity, irrespective of stress
stimulus [73]. This is crucial for insulin sensitivity, since
enhanced rate of JNK phosphorylation is associated with
glucose intolerance and insulin resistance in skeletal muscle
of obese mice, an effect which may be attenuated by long-
term (16-week) heat treatment (41.5∘C) and is also observed
in transgenic HSPA1A+/+ mice [14]. Heat treatment also
induced improvement of mitochondrial function, increasing
citrate synthase and 𝛽-hydroxyacyl-CoA-dehydrogenase (𝛽-
HAD) activity in soleus and extensor digitorum longus (EDL)
muscle [14]. Interestingly, a 12-week period of heat treatment
is unable to change fasting blood glucose of obese rats, but it
does attenuate insulin levels and decrease whole body glucose
clearance induced by HFD [72].
In obese HFD animals, phosphorylation of IRS1 in Tyr612
and the consequent downstream phosphorylation of Akt in
Ser473 and activation ofAS160 have been found to be reduced
in the skeletal muscle, while heat treatment reverted this
response in a process associated with HSPA1A expression
[72]. Moreover, JNK inhibition has been demonstrated to
rapidly occur in a dose-dependent manner in heat-shocked
NIH 3T3 fibroblasts via interaction between JNK1 and
HSPA1A [74]. Finally, studies have demonstrated that HSP70
is able to bind to the insulin receptor enhancing its recycling
rate after heat shock [75, 76], which suggests that heat shock
proteins may have direct influence upon insulin receptor
function and activity.
4. Role of eHSP70 in Insulin Resistance and
𝛽-Cell Dysfunction
In contrast to its intracellular proinsulin signaling and anti-
inflammatory effect, extracellular HSP70 (eHSP70) when
chronic elevated is associated with inflammatory condi-
tions, including T2DM [17]. Other cells (e.g., lymphocytes,
macrophages, epithelial cells, dendritic cells, neuronal cells,
and hepatocytes) have been reported to release HSP70 pro-
teins via (i) active mechanisms, such as vesicular secretion
(classical pathway in rest conditions), (ii) lipid rafts, or (iii)
exosomes [77]. Once in the bloodstream, eHSP70 may act as
a paracrine factor [77].
With respect to the extracellular compartment, eHSP70
can bind to TLR2 and TLR4 in a variety of cells, [77] leading
to the activation of proinflammatory pathways via MyD88
and TIRAP that signal downstream to NF-𝜅B via IRAK4,
TRAF6, and IKK and inducing JNK activation via MEKK4/7
[49, 78], although high-affinity binding of eHSP70 to other
surface receptors has also been described [79]. The signal
triggered by eHSP70 promotes typical immunoinflammatory
responses directed to the combat of infections and bacterial
infiltration through the production and release of NO∙ and
proinflammatory cytokines, such as TNF𝛼 and IL1𝛽 [80].
Moreover, eHSP70 responses are positively associated with
classical inflammatory parameters such as CRP, fibrinogen,
and monocyte counts [81] being commonly found in clinical
situations, in which a danger signalization to immune system
must be required [77]. Indeed, increased serum HSP70 has
been reported in chronic and age-related diseases [82–84].
Interestingly, during conditions in which individuals are
chronically exposed to elevated eHSP70 levels, changes in
the iHSP70 content are also observed [14, 65]. In fact, in
T2DM iHSP70 is reduced in insulin-dependent tissues such
as skeletal muscle and adipose tissue [14, 17, 65] while the
eHSP70 is elevated.This profile is commonly found in T2DM,
where obesity is an aggravating factor for the undesirable
high eHSP70/iHSP70 ratio [17]. In addition, serum HSP70
levels were found to be higher in long-term (>5 years) T2DM
patients as compared to newly diagnosed ones [85].
High eHSP70-mediated stimulation of TLR2/4 may
severely jeopardize insulin signaling. Accordingly, TLR2/4-
dependent activation of JNKs promotes phosphorylation of
IRS-1 at Ser307 in rodents (equivalent to Ser312 in humans)
leading to inhibition of Akt activation [86] and, consequently,
to a reduced glucose uptake by sensitive tissues and to a state
of resistance to insulin action. Moreover, it has been shown
that TLR2 is central to palmitate-induced insulin resistance
[87], via JNK-mediated phosphorylation of IRS1/2 [88]. On
the other hand, loss-of-function mutation in TLR4 prevents
HFD-induced obesity and insulin resistance [89].
Ser307 phosphorylation of rodent IRS-1 may also be
elicited by inflammatory cytokines via IKK, in a process that
can be inhibited by cp-PGs [90], which are powerful anti-
inflammatory autacoids possessing iHSP70-inducing capac-
ity [40]. Indeed, inhibitory Ser307 phosphorylation of IRS-1
is a physiologicalmechanismof feedback inhibition of insulin
signal that is under the control of both insulin/IGF1 and
inflammatory cytokines, though via different downstream
pathways [91]. TLR4 expression and signaling dependent on
eHSP70 is increased in obese and T2DM subjects, an effect
that can explain the high basal rate ofMAPKphosphorylation
and NF-𝜅B activation found in these patients [92–95]. The
above findings help to explain why inhibition or absence of
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TLR4 confers protection against insulin resistance in skeletal
muscle [96], adipose tissue, and liver [26, 97].
Finally, as recently found, eHSP70 is positively correlated
with insulin resistance and inflammation in elderly people.
This may indicate a role for eHSP70 in impairment of insulin
signaling in the skeletal muscle that occurs with advanced age
and in T2DM [98]. In addition, the same group has shown
that chronic exposure of 𝛽-cells and islets to increased con-
centrations of eHSP70 results in 𝛽-cell death and altered cell
bioenergetics, a phenomenon that, apparently, is mediated
through TLR-2 and TLR-4 activation [98]. Since, in T1DM
there is a dramatic increase in eHSP70 and in T2DM and
aging there is a slow chronic increase in the concentration
of this protein, we educe that chronic exposure of pancreatic
𝛽-cells to eHSP70 may lead to 𝛽-cell failure and loss of
functional integrity in vivo.
5. The eHSP70 to iHSP70 Ratio: The
Chaperone Balance Hypothesis
Based on the previous discussion, while iHSP70 is clearly
protective, antiapoptotic, anti-inflammatory, and associ-
ated with normal insulin sensitivity, eHSP70 is related to
a proinflammatory response, decreased expression of the
anti-inflammatory iHSP70, and reduced insulin sensitivity.
Because of this, we suggest that the ratio of compartmental
distributions of HSP70 between extra- and intracellular
locations may determine the outcome of the inflammation
and its associated insulin resistance.
In a recent study, our group observed that the ratio
between plasma eHSP70 and iHSP70 in lymphocytes from
rats submitted to different loads of acute exercise can indicate
the inflammatory status (Heck et al., manuscript in prepa-
ration). Accordingly, assuming the ratio 𝑅 = [eHSP70]/
[[iHSP70] = 1 for the controls (resting, unstimulated),
moderate exercise produces a shift in 𝑅 to up to ca. 5,
which is paralleled by an elevation in inflammatory markers
and stimulation of cell proliferation. 𝑅 values higher than
5 denote an exacerbated proinflammatory response. Con-
versely, 𝑅 values between 0 and 1 indicate a predominantly
anti-inflammatory status. Thus, changes in the ratio between
extra- and intracellular HSP70 emerge as a potentially new
biomarker for inflammation and as a very sensitive indicator
of inflammatory status.
We applied this simple mathematical calculation to pub-
lished data from studies elsewhere. For instance, Yang and
collaborators have investigated the correlation between the
level of exposure to pollution and eHSP70 in steel workers
[99]. From the data obtained in this study, we calculated
𝑅 (plasma to lymphocyte ratio) as 5.5, 6.5, and 8.8, respec-
tively, for low, moderate, and high exposure, as compared
to controls (𝑅 = 1.0). We applied the same calculation
to the data by Rodrigues-Krause and colleagues’ obesity-
diabetes study [17], in which HSP70 was investigated in
healthy obese (considered the controls herein), nonobese
T2DM and in obese T2DM patients. In this case, settling
controls as 𝑅 = 1.0, we get 1.8 for T2DM and 6.0 for obese
T2DMpatients in which inflammatory unbalance was found.
Although healthy lean subjects had not been evaluated in
this work, it is likely that such 𝑅 marks should be even
higher if 𝑅 were taken in comparison with such controls.
Additionally, changes in 𝑅 calculation seem to be valid
during heat exposure as 𝑅 values correlated with the heat
exposure of peripheral blood mononuclear cells to different
temperatures within a physiological range. Accordingly, [100]
heat-shocked cells concomitantly measured HSP70 at 37∘C
(𝑅 = 1.00), 39∘C (𝑅 = 1.45), 42∘C (𝑅 = 0.65), and
43∘C (𝑅 = 0.48). Interestingly, at 45∘C, in which cells are
known to trigger JNK-dependent prosurvival inflammatory
pathways [74], 𝑅 value was calculated as 1.97, confirming
proinflammatory expectations. Moreover, in a combined
protocol of exercise training (60min during 11 days in a tread-
mill, 1.69–2.20m⋅s−1, 1% grade) and heat acclimation (rectal
temperature elevation by 1∘C for the duration of the exercise
sessions at 40∘C room temperature), [101] have observed, in
human volunteers, HSPA1A alterations (in plasma and total
leukocytes) that, after conversion to 𝑅 values, furnish the
following picture: before training, 𝑅 values were 1.11 at rest
and 0.51 two days after the primary test; after training and
acclimation, 𝑅 values were 0.22 at rest and 0.27 two days after
the last training session. These values can be explained by
the fact that eHSP70 plasma contents raised by ca. 50% in
untrained individuals evaluated 48 h after the priming test,
while under the same circumstances, iHSP70 was found to
be 2.9-fold the remaining values. On the other hand, exercise
training combined with heat acclimation evoked a 4.2-fold
enhancement in intracellular HSPA1A contents (hence, an
anti-inflammatory response) which remained unaltered 48 h
after the last session, while eHSP70 did not change any more,
remaining near the rest of values observed in untrained
volunteers.
The above observations led us to postulate that 𝑅 values
and, particularly, changes in 𝑅 values could be used as a
predictor gauge for the inflammatory response that culmi-
nates in insulin resistance and diabetes, despite the method
used to assess intra- and extracellular HSP70 contents.
Notwithstanding, 𝑅 values may be also useful for application
in several other inflammatory diseases and conditions besides
being of value in controlling exercise impact over inflam-
matory status. Furthermore, since eHSP70 and iHSP70 are
directly related to insulin sensitivity, 𝑅 value application in
diabetes appears to be straightforward. Figure 1 summarizes
this hypothesis.
6. Changing R Values: The Role of
Physical Exercise
As discussed above, eHSP70 to iHSP70 ratio (represented by
𝑅 values) may determine the fate of the insulin sensitivity
towards either its improvement (lower ratio) or its reduc-
tion/impairment (higher ratio). In this regard, strategies
capable of changing the HSP70 contents, in the intra- or
extracellular space, or both compartments, are likely to be
used as a therapeutic strategy for the prevention or treatment
of T2DM and its efficiency could be precisely followed by the
assessment of 𝑅 values during the course of such treatment.
In this sense, physical exercise fulfills all the prerequisites: it
is a known modulator of eHSP70 (whose levels drop under





























































Figure 1: The chaperone balance. Adipose tissue expansion leads to chronic release of proinflammatory cytokines and adipokines. The
low-grade inflammation can induce (i) activation of NF-𝜅B-dependent inflammatory pathways leading to the blockage of iHSP70 and to
insulin resistance, (ii) release of proinflammatory eHSP70 chronically from immune cells, and (iii) ROS and RNS, oxidative/nitrosative
stress that leads to protein damage and denaturation. eHSP70 is increased as a danger signal and to combat the plasma oxidative damage;
however, when chronically elevated, it (i) induces further immune activation and proinflammatory response and (ii) activates TLR and the
inflammatory pathway leading to the reduction of HSF-1 activation and eventually to reduced iHSP70. Lower iHSP70 causes (i) reduced
insulin sensitivity, (ii) intensification of the NF-𝜅B activation and inflammation, and (iii) reduced antioxidant, antiapoptotic, and anti-
inflammatory capacity. The long-term insulin resistance determines the onset of diabetes, completing this positive feedback mechanism.
Lower panels: when the eHSP70/iHSP70 ratio chronically changes in favor of eHSP70, the “insulin sensitivity button” is switched off and 𝑅
values ([eHSP70]/[iHSP70]) rise; exercise induces iHSP70 expression while the release of eHSP70 responds in an opposite manner. 𝑅 values
between 0 and 1 indicate an anti-inflammatory status and between 1 and 5 indicate an optimum immunoinflammatory surveillance status,
while 𝑅 values above 5 suggest an undesirable chronic proinflammatory status.
exercise training) and iHSP70 (which tends to rise under the
same circumstances). In other words, although acute exercise
bouts signalize a “stressful situation” to all physiological
systems (please see Heck et al. 2011 for review [102]) leading
to augmented but just momentary eHSP70 plasma levels
[103], exercise training or regular physical activity tends to
reduce the stressful impact of each exercise session, leading to
decreased eHSP70 and enhanced iHSP70 during the course of
training. For this reason, exercise can also be used as a tool to
decrease or maintain the normal 𝑅 values and, consequently,
optimum insulin sensitivity. In fact, improvement of glucose
uptake and storage aswell as increase in the oxidative capacity
of different muscle fibers has been shown to be associated
with increased iHSP70 expression in the skeletal muscle [14,
66]. Moreover, physical exercise has been proposed as an
alternative strategy for T2DM patient treatment by virtue of
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its iHSP70 enhancing capacity: patients submitted to acute
exercise bouts or moderate training have shown significant
increase in muscle HSP70 expression [66, 104], which is
directly associated with reduction of insulin resistance [14,
72].
Exercise-induced expression of iHSP70 in skeletal muscle
has a major role in restoring muscle metabolic functionality;
besides, it provides cytoprotection to damaged cells. Such
an iHSP70 inducing ability has been shown as a resultant
in different protocols of exercise, including eccentric, con-
centric not damaging, aerobic, or resistive, all of which are
capable of inducing intramuscular HSP70 expression [104–
106]. Although time and intensity of the physical effort are
determinant factors to increase of intramuscular HSPA1A,
its rise may be detectable just 2 h after the onset of an acute
exercise session, when HSPA1A mRNA expression peaks
[107]. Moreover, exercise-induced iHSP70 presents a time
and intensity dependence [108].
Since iHSP70 family members promote the facilitation of
protein transport intomitochondria, allowing and improving
structural integrity of the organelle during fast energy flow,
iHSP70 content has been correlated with an increase in
the oxidative capacity of muscle cells. Several studies have
demonstrated the relationship between high iHSP70 levels
in skeletal muscle and increased activity of mitochondrial
enzymes after short training period [109]. On the contrary,
decreased mitochondrial function is known to be associated
with the accumulation of intramyocyte triglycerides (and its
byproducts), insulin resistance, and diabetes. For this addi-
tional reason, exercise-induced iHSP70 expression can lead
to improvements in metabolite oxidation and, consequently,
insulin sensitivity.
As regarded above, HSF-1 is negatively regulated by
GSK3𝛽, a serine/threonine kinase that phosphorylates this
factor on Ser303, keeping it in its inactive form in the cytosol.
During acute physical exercise, GSK3𝛽 activity has been
found to be nevertheless 30% decreased in Vastus lateralis
muscle, concomitantly with Akt phosphorylation in Ser473
and glycogen synthesis (GS) activation [110]. In addition, a
direct relation between iHSP70 and IL-6 has been reported.
During physical exercise, IL-6 can be expressed [111] and
released [112] by the skeletal muscle and, within extracellular
space, binds to the IL-6 receptor in an autocrine action
[113]. Interestingly, the “myokine” IL-6 has also been found
to induce HSF-1 translocation to the nucleus upregulating
heat-induced HSP70 gene, protein expression, and activity in
human hepatic cells in a PI3K/Akt/GSK3𝛽 dependent path-
way [114]. On the other hand, absence of IL-6 is associated
with decreased expression of HSPA1A in skeletal and cardiac
muscle of mice challenged with LPS, although IL-6 seems not
to be required for exercise-induced HSP expression [115].
The molecular mechanism(s) underlying the connection
between iHSP70 expression and increased energy flow are not
clear yet. However, changes in ATP/ADP ratio seem to work
as a signal to the activation of different kinases, such asAMPK
that is capable of decreasing GSK3𝛽 activity [116]. AMPK
is also regulated by Ca2+ during muscle contraction that
activates Ca2+/calmodulin protein kinase kinase (CaMKK) in
an LKB1-dependent pathway [117].Thus, AMPK activation as
result of muscle contractionmay act as a stimulus for iHSP70
induction in a HSF1-dependent way.
Exercise is also known to induce eHSP70 release and
accumulation into the circulation [107]. While the source
of the eHSP70 during the exercise is still in debate, current
data have suggested that hepatosplanchnic tissues should be
involved [103]. Additionally, 𝛼1 adrenoreceptors in the liver
seem to participate [118, 119] in a way that is dependent
on exercise intensity, type, duration, and training status
[120]. In addition, recent data suggests eHSP70 concentration
increases once systemic temperature and sympathetic activity
exceed minimum endogenous criteria and is likely to be
modulated by large and rapid changes in core temperature
[121]. However acute physical exercise is an inducer of
eHSP70 release into the blood and exercise is not a factor
of maintenance of high eHSP70 indefinitely, because chronic
exercise (training) suppresses eHSP70 levels [101]. Hence, the
expected deleterious effects of long-term exposure to high
eHSP70 concentrations are never attained.
In response to eHSP70, macrophages can release IL-
1𝛽, IL-6, and TNF𝛼 [122], all cytokines involved in insulin
resistance. Interestingly, in trained obese Zucker rats, the
macrophage cytokine release profile in response to eHSP70
is changed. In this case, the macrophages from obese Zucker
rats released less IL-1𝛽 and TNF𝛼 but more IL-6 than
macrophages from lean animals, indicating that habitual
exercise improved the release of proinflammatory cytokines
by macrophages [122].
7. Concluding Remarks
Taken as a whole, the above findings clearly indicate that
while iHSP70 is protective and anti-inflammatory being asso-
ciated with normal insulin sensitivity, eHSP70 chronically
produced in response to low-grade inflammation (but not to
chronic exercise) is related to a proinflammatory response,
decreased expression of iHSP70, and reduced insulin sensi-
tivity. Therefore, we suggest that the ratio of HSP70 contents
between the extra- and intracellular compartments may
dictate the outcome of the inflammation and associated
insulin resistance (Figure 1). Since exercise is able tomodulate
both eHSP70 and iHSP70, it is reasonable to predict that
exercise is the most efficient and powerful tool currently
available to normalize and/ormaintain eHSP70/iHSP70 ratio
at appropriate levels, thus preventing T2DM.The appropriate
type, intensity, duration, and frequency of exercise that best
fit each condition need to be determined.
The versatility of the HSP70 to induce different
inflammation-related responses according to its location
(intra- versus extracellular) places this protein as a master
regulator for the fine-tuned control of the immune system:
while iHSP70 induces inactivation of NF-𝜅B, eHSP70
induces the opposite effect. Thus, we suggest that the
eHSP70/iHSP70 ratio may represent a better marker for the
immunoinflammatory status of the whole body in exercise
as well as in many types of diseases. Finally, we advocate
that 𝑅 values could be useful not only in assessing the
course of therapeutic approaches in obesity-induced insulin
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insensitivity and diabetes, but also to evaluate inflammatory
status in inflammation-related diseases (e.g., atherosclerosis
and other cardiovascular diseases, rheumatoid arthritis,
sepsis, and obesity-related nonalcoholic fatty liver disease)
as well as in exercise training directed to immunosuppressed
and cardiovascular patients. Hence, the above propositions
may have an important diagnostic value for such patients,
since “HSP70 status” determined through 𝑅 values may be
easily obtained from the ratio of extracellular (plasma) to
intracellular (circulating blood leukocytes or mononuclear
cells) HSP70 content from a blood sample.
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